Press Releases

Bioengineered Organ Implant Developer Biostage to Present at Marcum and LD Micro Investor Conferences on June 2nd in NYC and June 7th in LA

HOLLISTON, Mass., May 19, 2016 /PRNewswire/ -- Biostage, Inc. (NASDAQ: BSTG), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the esophagus, bronchus and trachea, today announced that CEO Jim McGorry and CFO Tom McNaughton will present at the Marcum and LD Micro investor conferences on Thursday, June 2nd at 9:30 am ET and Tuesday, June 7th at 4 pm ET respectively.



Marcum Microcap Conference:


Thursday, June 2, 2016 9:30 am ET



Grand Hyatt New York, Park Avenue at Grand Central, New York, NY 10017


LD Micro Invitational Conference:


Tuesday, June 7, 2016 4:00 pm ET / 1:00 pm PT

Webcast/ Replay:


Luxe Sunset Boulevard Hotel, 11461 Sunset Blvd, Los Angeles, CA 90049

About Biostage, Inc.: 
Biostage is a biotechnology company developing bioengineered organ implants based on the company's new Cellframe™ technology which combines a proprietary biocompatible scaffold with a patient's own stem cells to create Cellspan™ organ implants. Cellspan implants are being developed to treat life-threatening conditions of the esophagus, bronchus or trachea with the hope of dramatically improving the treatment paradigm for patients. Based on its preclinical data, Biostage has selected life-threatening conditions of the esophagus as the initial clinical application of its technology.

Cellspan implants are currently being advanced and tested in a collaborative preclinical study. This testing is expanding the base of preclinical data in support of Biostage's goal of filing an Investigational New Drug (IND) application with the U.S. FDA in late 2016. The IND will seek approval to initiate clinical trials for its esophageal implants in humans.

Forward-Looking Statements: 
Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements in this press release include, but are not limited to, statements relating to Biostage's expectations regarding the completion, timing, pricing and size of the offering described in this press release, whether expressed or implied; development expectations and regulatory approval of any of our products, including those utilizing our Cellframe technology, by the FDA, EMA, MHRA or otherwise, which expectations or approvals may not be achieved or obtained on a timely basis or at all; or success with respect to any collaborations, clinical trials and other development and commercialization efforts of our products, including those utilizing our Cellframe technology,  which such success may not be achieved or obtained on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, our ability to obtain and maintain regulatory approval for our products; plus other factors described under the heading "Item 1A. Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 or described in our other public filings. Our results may also be affected by factors of which we are not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Biostage expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.

Twitter: BiostageIR

StockTwits: BiostageIR

Media/Investor Relations Contact:


Tom McNaughton

David Collins, Bill Jones, Helen Sun

Chief Financial Officer 

Catalyst Global LLC


212-924-9800 w; 917 734-0339 m

Logo -

SOURCE Biostage, Inc.